Tag: Lou Gehrig’s disease

  • Nation & World

    Blocking tau may help ALS patients

    Mass. General study uncovers potential new treatment strategy for disease.

    2 minutes
    Tau-treated cells.
  • Nation & World

    Investigational ALS drug slows progression

    An experimental medication that was recently shown to slow the progression of ALS has now demonstrated the potential to also prolong patient survival.

    3 minutes
    Neuron
  • Nation & World

    The ‘spiritual leader’ of WHRB

    After 58 years of helping Harvard student radio station WHRB build toward excellence, David Elliott steps back to undergo ALS treatment.

    6 minutes
    Aaron Fogelson, '19, on left, HRB president., and David Elliott
  • Nation & World

    Research suggests new avenues for attacking ALS

    Harvard researchers have found evidence that bone marrow transplantation may one day be beneficial to a subset of patients suffering from ALS.

    3 minutes
  • Nation & World

    Hope against disease targeting children

    Harvard Stem Cell Institute researchers studying spinal muscular atrophy have found molecular changes that help trigger the genetic disease in children.

    4 minutes
  • Nation & World

    A new stem cell advance

    Collaborating with scientists elsewhere, Harvard Stem Cell Institute researchers have devised two methods for using stem cells to generate the type of neurons that help regulate behavioral and basic physiological functions in the human body, such as obesity and hypertension, sleep, mood, and some social disorders.

    3 minutes
  • Nation & World

    Progress against ALS

    Studies begun by Harvard Stem Cell Institute scientists eight years ago have led to a report that may be a major step in developing treatments for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.

    4 minutes
  • Nation & World

    New hope for treating ALS

    Harvard stem cell scientists have discovered that a recently approved medication for epilepsy might be a meaningful treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, a uniformly fatal neurodegenerative disorder.

    6 minutes
  • Nation & World

    High-calorie feeding may slow progression of ALS

    In a small study by Harvard-affiliated Massachusetts General Hospital, increasing the number of calories consumed by patients with amyotrophic lateral sclerosis (ALS) may be a relatively simple way of extending their survival.

    4 minutes
  • Nation & World

    Big boost in drug discovery

    Using a new, stem cell-based, drug-screening technology that could reinvent and greatly reduce the cost of developing pharmaceuticals, researchers at the Harvard Stem Cell Institute have found a compound that is more effective in protecting the neurons killed in amyotrophic lateral sclerosis than are two drugs that failed in human clinical trials.

    5 minutes
  • Nation & World

    New avenue in neurobiology

    Harvard stem cell biologists have proven that it is possible to turn one type of already differentiated neuron into another inside the brain, and their findings may have enormous implications for the treatment of neurodegenerative diseases.

    4 minutes
  • Nation & World

    A treatment for ALS?

    According to researchers, results from a meta-analysis of 11 independent amyotrophic lateral sclerosis (ALS) research studies are giving hope to the ALS community by showing, for the first time, that the fatal disease may be treatable.

    3 minutes
  • Nation & World

    Link found between ALS and SMA

    Scientists have long known the main proteins that lead to the development of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), respectively. Now research shows that these two motor neuron diseases likely share a pathway that leads to the development of disease.

    3 minutes
  • Nation & World

    Fixing the way we fix the brain

    With neurodegenerative diseases affecting millions and having the potential to bankrupt the U.S. health care system, Harvard Medical School, seven pharmaceutical companies, and the Massachusetts state government have formed the Massachusetts Neuroscience Consortium. The goal: to offer new collaborative research models.

    8 minutes
  • Nation & World

    Slowing ALS symptom progression

    Harvard researchers find that treatment with dexpramipexole — a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell’s energy — appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS).

    4 minutes